Previous close | 113.35 |
Open | 110.31 |
Bid | 0.00 x 900 |
Ask | 0.00 x 900 |
Day's range | 107.71 - 111.50 |
52-week range | 31.04 - 120.48 |
Volume | 923,645 |
Avg. volume | 1,198,829 |
Market cap | 18.043B |
Beta (5Y monthly) | 1.50 |
PE ratio (TTM) | 69.25 |
EPS (TTM) | 1.58 |
Earnings date | 02 Feb 2021 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 114.90 |
Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene and cell therapies, and consumer health products, today announced that it will release financial results for the second quarter of fiscal year 2021 ended December 31, 2020, before the market open on Tuesday, February 2, 2021. The Company’s management will host a webcast to discuss the results at 8:15 a.m. ET on the same day.
Ayala Pharmaceuticals (AYLA) saw a big move last session, as its shares jumped more than 13% on the day, amid huge volumes.